ABBN.SW: $86.50 ▲ 0.40 (0.46%)ASML.AS: $1,578.40 ▲ 17.60 (1.13%)ENR.DE: $160.60 ▼ -1.90 (-1.17%)GLEN.L: $532.40 ▼ -2.90 (-0.54%)IFX.DE: $81.31 ▲ 0.75 (0.93%)NOKIA.HE: $12.36 ▲ 0.36 (3.00%)RIO.L: $7,258.00 ▼ -6.00 (-0.08%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Tectonic Therapeutic, Inc.

TECX - NASDAQ

Identifiants & Marche

Ticker TECX
ISIN US8789721086
CIK 0001681087
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.